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Abstract
OBJECTIVE—To examine the longitudinal effects of comorbid anxiety disorders in youth with
bipolar spectrum disorder (BP).
METHOD—As part of the Course and Outcome of Bipolar Youth study, 413 youth, ages 7 to 17
years who met criteria for DSM-IV BP-I (n=244), BP-II (n=28), and operationally defined bipolar
disorder not otherwise specified (BP-NOS) (n=141) were included. Subjects were followed on
average 5 years using the Longitudinal Interval Follow-up Evaluation. Effects of anxiety on the
time to mood recovery and recurrence and percentage of time with syndromal and subsyndromal
mood symptomatology during the follow-up period were analyzed.
RESULTS—At intake and during the follow-up, 62% of youth with BP met criteria for at least
one anxiety disorder. About 50% of the BP youth with anxiety had ≥ 2 anxiety disorders.
Compared to BP youth without anxiety, those with anxiety had significantly more depressive
recurrences and significantly longer median time to recovery. The effects of anxiety on recovery
disappeared when the severity of depression at intake was taken into account. After adjusting for
confounding factors, BP youth with anxiety, particularly those with ≥ 2 anxiety disorders, spent
significantly less follow-up time asymptomatic and more time with syndromal mixed/cycling and
subsyndromal depressive symptomatology compared to those without anxiety.
CONCLUSIONS—Anxiety disorders are common and adversely affect the course of BP in
youth, as characterized by more mood recurrences, longer time to recovery, less time euthymic,
more time in mixed/cycling and depressive episodes. Prompt recognition and the development of
treatments for BP youth with anxiety are warranted.
Keywords
anxiety disorders; bipolar disorders; longitudinal study
INTRODUCTION
The frequency with which anxiety symptoms accompany manic and depressive states was
originally noted by Kraepelin, 1 and modern clinical and epidemiological studies also
confirm the presence of anxiety disorders in youth with bipolar disorders (BP). 2–5
While comorbid anxiety disorders have been linked to poorer prognosis and an increased
risk of suicide in youth with BP, 6 these observations are primarily cross-sectional in
nature. 2, 5 To our knowledge only 2 studies have investigated the effect of comorbid anxiety
disorders in youth with BP longitudinally. Masi et al. (2007)7 followed a sample of 224
youth with BP spectrum disorders for a minimum of 6 months, noting that those with
concurrent panic disorder (PD) showed less mood severity at baseline but greater persistence
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of illness during the follow-up compared to those without PD. Similarly, DelBello et al.,
(2007) 4 followed a group of 71 adolescents with BP-I for 1 year after discharge from the
hospital and observed more severe mood symptoms and lower rates of recovery amongst
those with comorbid anxiety disorders compared to those without anxiety.
Longitudinal studies in adults report similar associations; namely, that comorbid anxiety
confers greater affective morbidity, including less time spent with euthymic mood, 8–10
more severe depressive symptoms and more follow-up time in depression, 10, 11 more rapid
cycling, 8 increased time to episode remission, 8 and earlier relapse. 9 Comorbid anxiety has
also been associated with greater substance use, 8 poorer psychosocial functioning,8, 9 and
poorer response to pharmacological treatments. 10
In a prior publication, 12 we reported that anxiety disorders that were ascertained at intake
persisted in 50% of the youth with BP; persistence of anxiety disorders over the follow-up
period was defined as at least 50% of follow-up time meeting full-threshold DSM-IV anxiety
disorders criteria. Moreover, during approximately 5 years, 25% of the youth with BP who
did not have anxiety disorders at intake developed new onset anxiety disorders. In
comparison with youth who had anxiety disorders at intake, those who developed anxiety
disorders during the follow-up showed significantly more substance abuse (10/92, 40% vs.
5/162, 33%, χ2=6.4, p=0.01). There were no other between-group demographic or clinical
differences. Given the clinical implications and the existence of few longitudinal studies
examining the longitudinal effects of comorbid anxiety disorders in BP youth, we sought to
extend our prior findings and examine the impact of anxiety on the 5-year prospective
course and outcome of youth with bipolar spectrum disorders. Based on the literature, we
hypothesized that in comparison with BP youth without anxiety disorders, those with
anxiety disorders will have: 1) less recovery and more recurrences, and 2) less percentage of




The original sample of Course and Outcome of Bipolar Youth study (COBY) consisted of
446 youth (BP-I=260, BP-II =32, BP-NOS; n=154). In comparison with the 413 who
participated in this study, those who did not participate (n=33) showed significantly less any
anxiety disorders (39, 2% vs. 69.6%, χ2= 7.5, p=0.006). There were no other between-group
demographic or clinical differences. The present study included 413 youth, ages 7 to 17
years 11 months (12.6 ± 3.3 years old) who met criteria for Diagnostic and Statistical
Manual IV (DSM-IV) BP-I (n=244), BP-II (n=28), and operationally defined BP-NOS
(n=141) and were recruited primarily through clinical referrals from 3 academic medical
centers (University of Pittsburgh Medical Center, Brown University, and University of
California at Los Angeles). 13 To date, subjects have been prospectively interviewed on
average every 37.13 ± 20.4 weeks for a mean of 261.7 ± 94.1 weeks (approximately 5
years). At present, subject retention rate is 84.8%.
Because the DSM-IV criteria for BP-NOS are vague, the COBY study investigators set the
minimum inclusion threshold for the BP-NOS group as subjects who did not meet the DSM-
IV criteria for BP-I or BP-II but had a distinct period of abnormally elevated, expansive, or
irritable mood plus the following: (1) 2 DSM-IV manic symptoms (3 if the mood is
irritability only) that were clearly associated with the onset of abnormal mood, (2) a clear
change in functioning, (3) mood and symptom duration of a minimum of 4 hours within a
24-hour period for a day to be considered meeting the diagnostic threshold, and (4) a
minimum of 4 days (not necessarily consecutive) meeting the mood, symptom, duration, and
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functional change criteria over the subject's lifetime, which could be two 2-day episodes,
four 1-day episodes, or another variation 14.
Institutional review board approval was obtained at each site prior to subject enrollment.
After the Institutional Review Board approval, consent or assent was obtained from all
participants by project staff prior to administering study instruments.
Procedures
The methods used to evaluate the subjects were reported in detail elsewhere. 15 In summary,
at intake children and parents were interviewed for the presence of current and lifetime
psychiatric disorders using the Schedule for Affective Disorders and Schizophrenia for
School Age Children, Present and Lifetime Version (K-SADS-PL), 16 the Kiddie Mania
Rating Scale (K-MRS) 17 and the Depression Rating Scale (DRS) which was derived from
the respective sections of the KSADS-P. The index episode was defined as the current or
most recent episode assessed at intake. To ascertain the episode duration, time to recovery
was calculated from the onset of the index episode. Therefore, for some subjects the
duration of episode exceeds the length of prospective follow-up.
Parents were also interviewed at intake about their personal psychiatric history using the
Structured Clinical interview for DSM-IV Axis I Disorder (SCID), 18 and about first- and
second-degree psychiatric family history using a modified version of the Family History
Screen (FHS). 19 Socioeconomic status (SES) was measured using the Hollingshead 4-factor
scale. 20 Functional impairment was assessed using the Child Global Assessment Scale
(CGAS). 21 The child and parent Screen for Child Anxiety Related Emotional Disorder
(SCARED) 22 was used to evaluate severity of anxiety symptoms. Pubertal status and
equivalent Tanner Stage was assessed with the Petersen Pubertal Developmental Scale
(PDS). 23
Longitudinal change in psychiatric symptoms, functioning, and treatment exposure since the
previous evaluation were assessed using the Longitudinal Interval Follow-up Evaluation
(LIFE). 24 The LIFE was administered to adolescents and parents separately. When younger
children had problems timing their symptoms, they were interviewed with their parents. Any
discrepancies between the informants' responses were discussed and a summary score based
on all available information was determined. The LIFE evaluates the course of symptoms by
identifying change points, frequently anchored by memorable dates for the subject (e.g.,
holidays and beginning of school). The severity of ongoing symptoms, onset of new
symptoms, and episode polarity for BP since the last appointment are tracked using weekly
LIFE Psychiatric Status Rating (PSR) scores. Symptoms for each disorder were not double
counted.15 For DSM-IV mood disorders, the PSR scores range from 1 for no symptoms, 2 to
4 for varying levels of subthreshold symptoms and impairment, to 5 or 6 for full criteria with
different degrees of severity or impairment. 15 Most of the anxiety disorders were rated on a
6-point scale of 1 to 6, where 5 and 6 indicate presence of fulfilled DSM-IV symptoms
criteria (including impairment). For anxiety disorder NOS and separation anxiety disorders
(SAD), other comorbid disorders, and psychosis were assigned weekly scores on a 3-point
scale of 1 to 3, where 2 indicates subthreshold level of symptoms and 3 indicates presence of
full DSM-IV symptoms criteria (including impairment). Clinically relevant psychotic
symptoms were assigned a PSR score of 3 (definitely present) for delusions and/or
hallucinations. 15 Past and current pharmacological treatment was obtained using the
Psychotropic Treatment Record of the LIFE. Using this instrument the lifetime exposure to
antimanics (lithium, valproic acid, and atypical antipsychotics), antidepressants (mainly
selective serotonin reuptake inhibitors [SSRIs]), and stimulants were evaluated. Youth with
only specific phobia (e.g., fear of the dark) were excluded because simple phobias are
ubiquitous. 2, 12
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The percentage of follow-up weeks spent asymptomatic or symptomatic in the different
mood symptom categories during the entire follow-up period were computed based on the
PSR scores for each subject. Full recovery was defined as 8-consecutive weeks with a score
of ≤2 (minimal or no mood symptoms). 15, 25 Time to recovery from the index episode was
measured from the onset of the index episode. A recurrence (new episode) required a PSR
≥5, with duration of 1-week for mania/hypomania and 2-weeks for depression. 15 COBY
used the DSM-IV definitions for rapid cycling and mixed episodes. 15 Subsyndromal mixed
episodes were defined as not having full DSM-IV criteria for mixed episodes.
All assessments were conducted by research staff trained to reliably administer the
interviews; interview results were presented to child psychiatrists or psychologists, who
confirmed the diagnoses and the PSR scores. 15 The evaluators were not blind to diagnostic
group.
Statistical Analyses
Demographic and clinical differences between BP youth with versus without anxiety
disorders were evaluated using standard parametric and nonparametric statistics as
appropriate. The percent of subjects with recovery from mood episodes and recurrence were
compared using chi-square test and significant confounding variables were adjusted using
step-wise regression analyses. Time to recovery and recurrence after the index mood episode
were compared using survival analyses. Stepwise Cox proportional hazard regression,
keeping anxiety into the model, were utilized to adjust for between group demographic and
clinical variables with p-values< 0.1. Age onset of mood symptoms and duration of BP (r=
−0.58; p<0.0001) and DRS at intake and DRS during the most severe lifetime (r=0.55;
p<0.0001) were significantly correlated. Thus, for simplicity, only duration of BP and DRS
at intake was included in the analyses. Finally, the proportion of follow-up time (% weeks)
spent asymptomatic, with subsyndromal and syndromal mood symptomatology and
psychosis as measured by the PSR were analyzed using general linear models and adjusting
for any between group demographic and clinical differences. Given that the majority of
subjects with obsessive-compulsive disorder (OCD) or posttraumatic stress disorder (PTSD)
also met criteria for another anxiety disorder, 26 we analyzed the sample together. In
addition, exploratory analyses examining the effects of specific anxiety disorders on the




Sixty-two percent (256/413) of youth with BP met criteria for an anxiety disorder at intake
or at any time during the follow-up. Among those with any anxiety disorder, the prevalence
of specific anxiety disorders was as follows: 19.53% panic disorder, 46.09% SAD, 28.13%
social anxiety disorder, 43.36% generalized anxiety disorder (GAD), 23.44% OCD, 19.14%
PTSD, 17.19% anxiety-NOS, 7.42% agoraphobia. Approximately 55% of anxious subjects
had ≥ 2 anxiety disorders (50.8% excluding anxiety-NOS), particularly SAD and GAD. BP
youth with anxiety had significantly lower SES, were less likely to live with both natural
parents, and had greater length of follow-up compared to BP youth without anxiety (Table 1;
all p-values ≤0.03). There were no other between-group demographic differences.
Clinical Characteristics
As shown in Table 1, compared with BP youth without anxiety, BP youth with anxiety had
significantly earlier age of onset of mood symptoms, longer duration of BP, higher self- and
parent-rated depression and anxiety scores at intake and over follow-up, higher rates of past
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suicide attempts, and higher rates of physical or sexual abuse. In addition, BP youth with
anxiety had significantly higher lifetime rates of treatment with antidepressants and had
more family history of mania/hypomania, depression, and anxiety compared to BP youth
without anxiety (for all above noted comparisons p-values ≤0.02). There were no significant
differences in the history of lifetime psychosocial treatments between BP youth with and
without anxiety disorders.
Of all the above demographic and clinical univariate differences only the following factors
remained significant in the step-wise regression models: socioeconomic status, living with
both natural parents, duration of BP, DRS at intake, history of physical and sexual abuse,
family history of mania/hypomania, depression and anxiety, and follow-up time period.
These variables were entered in all the analyses described below.
Recovery From the Index Episode (Table 2 and Figure 1)
There were no between-group differences in the rates of recovery from the index mood
episode.
However, using survival analyses, BP youth with anxiety showed significantly longer
median time to recovery than those without anxiety (138.3 weeks vs. 86.6 weeks, χ2=8.88,
p=0.003). After adjusting for the above-noted significant confounding factors, the effects of
anxiety on time to recovery were no longer significant. However, when the DRS score at
intake was removed from the model, anxiety remained significantly associated with
recovery (p=0.02).
Recurrence After Recovery From the Index Episode (Table 2 and Figure 2)
Among youth who recovered from the index episode, those with anxiety were significantly
more likely to experience any mood recurrences (76% vs. 56.4%, χ2=15.12, p=0.0001) and
depression recurrences specifically (64.9% vs. 49.4%; F=5.33; p=0.02) when compared to
those without anxiety disorders. Similar results were obtained after adjusting for the above-
noted significant confounding factors. There were no between-group differences in the
median time to recurrence and to other polarity recurrences.
Week-by-Week Mood Symptom Analyses (Table 3)
BP youth with anxiety spent significantly less follow-up time asymptomatic and more
follow-up time with syndromal and subsyndromal mixed/cycling and depressive
symptomatology, and psychosis compared to BP youth without anxiety (all p-values
≤0.006). After adjusting for the above-noted significant confounding factors, anxious BP
youth continued to show significantly less time asymptomatic, more syndromal mixed/
cycling, and more subsyndromal depression when compared with non-anxious BP youth (all
p-values ≤0.03).
Within the anxious BP youth, in comparison with youth with one anxiety disorder, those
with ≥2 anxiety disorders showed significantly less follow-up time asymptomatic
(33.2±25.2 vs. 42.7±27; F=8.28; p=0.004) and more follow-up time with syndromal mood
symptomatology (21.8±20 vs. 15.1±17.8; F=7.71; p=0.006), syndromal depression
(8.7±11.5 vs. 4.5±8.1; F=10.50; p=0.001), and subsyndromal mixed/cycling (19.4±20.3 vs.
13.2±15.7; F=7.25; p=0.008). Exploratory analyses examining the effects of specific anxiety
disorders on the course of the mood symptomatology showed that in comparison with youth
with other anxiety disorders, those with social anxiety disorder or PTSD spent less follow-
up time asymptomatic and more time with syndromal depression. In addition, those with
PTSD spent more follow-up time with syndromal and subsyndromal mixed/cycling and
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psychosis, those with OCD more time with hypomanic symptomatology, and those with
panic disorder more time with syndromal depression (for all comparisons p-values≤0.04).
DISCUSSION
At intake and during the follow-up, 62% of youth with BP had at least one anxiety disorder
and about 50% of the anxious youth had ≥ 2 anxiety disorders, particularly SAD and GAD.
Survival analyses showed that compared to BP youth without anxiety disorders, those with
anxiety had significantly more depression episode recurrences and significantly longer
median time to recovery. After adjusting for significant confounding factors, the effects of
anxiety on recovery were significant when the severity of the depression at intake was
removed from the model. Week-by week mood symptom analyses showed that after
adjusting for confounding factors, BP youth with anxiety, particularly those with ≥2 anxiety
disorders, spent significantly less time asymptomatic, more time with syndromal mixed/
cycling and subsyndromal depressive symptomatology compared to those without anxiety.
Preliminary analyses indicated that youth with social anxiety disorder or PTSD and to lesser
degree panic disorder had worse mood outcome than youth with other anxiety disorders.
Our findings are consistent with prior clinical 5, 27 and epidemiologic studies 28 in which
anxiety disorders have been reported at high rates among youth with BP. Also, similar to the
adult BP literature, we found that BP youth with anxiety had significantly longer time to
recovery from the index episode and more mood recurrences, particularly depression
episodes, among those who recovered. 9
Consistent with evidence from the adult BP literature,9, 11 we found that BP youth with
anxiety have longer time to recovery than those without anxiety. However, as expected this
effect was confounded by the presence of depressive symptomatology. The Collaborative
Depression Study follow-up 29 also showed that recovery one year after intake was much
more likely for those BP patients whose index episode was purely manic than for those
whose index episode was depressed or cycling.
Present findings also converge with the adult BP literature in showing that comorbid anxiety
is associated with less time asymptomatic, 8–10, 30 more time with syndromal mixed/
cycling, 8, 31, 32 and more depressive symptomatology. 8, 10 In addition, we found that
having ≥2 anxiety disorders have a worse course of BP illness compared to those with only
one anxiety disorder8, 9 with social anxiety disorder and PTSD, and to a lesser degree panic
disorder, having the most negative impact on outcome. 8 Furthermore, those with OCD had
more time with hypomanic symptomatology. 33 Interestingly, Otto et al. 9 documented a
negative impact of anxiety disorders on BP course, even when anxiety was assessed during
periods of relative euthymia, suggesting that a worse course of BP in adults with anxiety
comorbidity may reflect a unique biological subtype of BP. The above noted findings are
similar to those found in the large depression literature noting the deleterious effects of
concomitant anxiety disorders in unipolar depression. 34 In a prior COBY article using the
same sample as the present study, we reported that anxiety disorders predated the onset of
BP. 26 In addition, in a second paper we found that about 80% of the anxiety disorders
persist and tend to be of the same type during the follow-up.12
The continuity between anxiety comorbidity and depressive morbidity raises two notable
questions. The first is whether anxiety phenotypes in these subjects are truly independent
factors that confer risk of subsequent depressive episodes, or a variable expression of a
single propensity. In line with this possibility, while evidence is substantial that genetic
factors impact individual differences in liability to anxiety and depression—generalized
anxiety disorder in particular—the 2 phenotypes co-occur frequently in clinical and
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epidemiological samples, 35 due largely to a sharing of common genes, 36 whereas
individual specific environmental effects may account for the primacy of anxiety in some
individuals versus depression in others. 36 Second, lower socioeconomic status, less
likelihood of living with both natural parents, and higher rate of abuse may have an
important role to play as well. 37, 38 The association of traumatic events (e.g., history of
physical and sexual abuse) with anxiety comorbidity in this cohort is consistent with a
voluminous literature on the role of early life adversity in the programming of anxiety
proneness and other symptoms of poor control of affective arousal via neurotoxic,
inflammatory, and epigenetic mechanisms. 39 But whether or not these associations are
robust in the context of bipolar versus non-bipolar affective disorder remain unresolved.
Despite the high rates of comorbid anxiety and its association with negative course and
outcome of BP, there are no studies regarding the pharmacological or psychosocial
management of anxiety disorders in youth with BP. This is very relevant because currently
the main pharmacological treatment for anxiety disorders in youth is the SSRIs. 40–42
However, the use of antidepressants may worsen the symptoms of patients with BP 43 and
the presence of anxiety may be a predictor of treatment emergent mania. 44 At this time,
there are no controlled trials and very few open trials examining the efficacy of
pharmacotherapy or psychotherapy aimed at managing anxiety disorders in BP illness, 45
with an open study of divalproex sodium 46 and an open study of group cognitive-behavioral
therapy 47 suggesting possible benefit. Therefore, given the absence of compelling efficacy
data to guide clinical practice for this population, it is not surprising that often they receive
inadequate treatment. 48 Furthermore, given the differential effects of individual anxiety
disorders on the course of BP in youth, it might be helpful to incorporate specific treatment
protocols, including CBT, specifically targeted for these comorbid conditions.
The above-noted results need to be taken in the context of the limitations of this study. First,
despite the efforts to obtain precise longitudinal information the data collected were subject
to retrospective recall bias. 4, 49 Second, the effect of psychosocial treatments on the course
of BP youth with anxiety disorders was not examined. Third, no psychiatric control group
was included. Fourth, we only collected information on the rates of overall psychosocial
treatments and not specific types of psychotherapy, such as cognitive behavior therapy.
Finally, as most subjects were Caucasian and were recruited primarily from outpatient
clinics, and to a lesser extent, from inpatient settings, the generalizability of the observations
to other populations remains uncertain. Nevertheless, a community-based study of non-
referred adolescents with BP reported similarly high rates of comorbid anxiety disorders. 3
In summary, anxiety disorders are common and adversely affect the course of BP in youth,
as characterized by more mood recurrences, longer time to recovery, less time
asymptomatic, more syndromal mixed/cycling, and more subsyndromal depression
compared to those without anxiety. Prompt recognition and the development of psychosocial
and pharmacological treatments for anxious youth with BP are warranted.
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• 62% of youth with bipolar disorder (BP) met criteria for at least one anxiety
disorder and about 50% of the anxious BP youth had ≥ 2 anxiety disorders.
• Anxiety disorders are adversely affect the course of BP in youth, as
characterized by less time euthymic, more time in mixed/cycling and depressive
episodes compared to BP youth without anxiety.
• Prompt recognition and the development of treatments for anxious BP youth are
warranted.
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Recovery from index episode among youth with bipolar disorders with versus without
anxiety disorders.
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Recurrence after recovery from index episode among youth with bipolar disorder with
versus without anxiety disorders.
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Table 1









Age 12.6±3.3 12.7 ± 3.2 |t| = 0.25 0.80
Sex, female (%) 48.4 43.3 χ2 = 1.03 0.31
Race, White (%) 81.3 83.4 χ2 = 0.32 0.57
SES 3.3 ± 1.2c 3.6 ± 1.2 |t| = 2.96 0.003
Living with both natural parents (%) 37.9 49.0 χ2 = 4.97 0.03
Pubertal Status
  I 25.4 30.1
  II–III 29.2 24.8 χ2 = 1.12 0.6
  IV–V 45.4 45.1
Follow-up period (weeks) 271.4±92.2 245.9±95.3 |t| = 2.70 0.007
Clinical Characteristics
BP Subtype (%)
  BP-I 57.0 62.4
  BP-II 8.6 3.8 χ2 =3.76 0.15
  BP-NOS 34.4 33.8
Age Onset of Mood Symptoms a 8.0±3.8 9.0±4.3 |t| = 2.54 0.01
Duration of BP b 4.8±3.2 3.7±2.5 |t| = 3.88 0.0001
Mania Rating Scale
  Intake 23.3±11.8 22.2±12.6 |t| = 0.83 0.41
  Most Severe Lifetime 34.5±7.4 33.7±9.0 |t| = 0.77 0.44
Depression Rating Scale
  Intake 17.0±9.9 10.8±9.5 |t| = 6.28 <.0001
  Most Severe Lifetime 24.8±9.8 19.4±11.3 |t| = 4.63 <.0001
Age of Onset of Anxiety Disorders 8.9±5.1
SCARED
  Child-Intake 28.6±17.0 18.4±17.5 |t| = 5.33 <.0001
  Parent-Intake 30.7±15.6 15.7±12.2 |t| = 10.16 <.0001




















ADHD (%) 61.7 55.4 χ2 = 1.60 0.21
ODD (%) 35.9 44.0 χ2 = 2.63 0.11
CD (%) 12.9 10.2 χ2 = 0.68 0.41
SUD (%) 10.2 5.7 χ2 = 2.46 0.12
Suicide Attempt (%) 34.4 21.7 χ2 = 7.57 0.006
History of Physical or Sexual Abuse (%) 25.0 10.8 χ2 = 12.4 0.0004
Psychotic Symptoms (%) 23.8 19.8 χ2 = 0.94 0.33
CGAS
  Intake 55.2±11.2 54.1±13.8 |t| = 0.85 0.39
  Most Severe Lifetime 37.6±11.4 37.4±9.0 |t| = 0.12 0.91
Lifetime Psychosocial Treatment (% Yes) 99.6 98.7 F=1.05 0.56
Lifetime Pharmacological Treatment (% Yes)
Any Psychotropics 95.3 96.2 χ2 = 0.18 0.68
Antimanics 79.3 84.7 χ2 = 1.88 0.17
Antidepressants 63.3 42.7 χ2 = 16.73 <.0001
Stimulants 58.2 52.9 χ2 = 1.13 0.29
Psychiatric Family History (% of subjects with at least one 1st or 2nddegree relative)
Mania/Hypomania 55.9 42.7 χ2 = 6.77 0.009
Depression 86.7 74.5 χ2 = 9.84 0.002
Anxiety Disorder 68.4 57.3 χ2 = 5.15 0.02
Any Substance Use Disorder 71.9 64.3 χ2 = 2.59 0.11
Suicide Attempt 42.2 38.2 χ2 = 0.64 0.43
Note: ADHD = attention-deficit/hyperactivity disorder; BP = bipolar disorder; BP-I = bipolar I disorder; BP-II = bipolar II disorder; BP-NOS =
bipolar disorder not otherwise specified; CD = conduct disorder; CGAS = Child Global Assessment Scale; F = Fisher exact test; ODD =
oppositional defiant disorder; SCARED = Screen for Child Anxiety Related Emotional Disorder; SES = socioeconomic status; SUD = substance
use disorder.
a
Age 4 is set as the minimum value.
b
Calculated from age at onset of any DSM mood episode.
c
Equivalent to middle class.
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Table 2










n % n %
Rate of Recovery 217/256 84.8 140/157 89.2 χ2=1.61 0.20
Rate of Recurrence a 165/217 76.0 79/140 56.4 χ2=15.12 0.0001
Time to recovery from the index episode, weeks b 138.29 86.57 log-rank χ2= 8.88 0.003
Time to recurrence, weeksc 37.00 48.00 log-rank χ2=3.23 0.07
Note:
a
Recurrence required either 1 week of Psychiatric Status Rating Scales scores ≥5 for mania/hypomania or 2 consecutive weeks of Psychiatric
Status Rating Scales scores ≥5 for depression
b
The index episode was defined as the current or most recent episode assessed at intake. To ascertain the episode duration, time to recovery was
calculated form the onset of the index episode. Therefore, for some subjects the duration of episode exceeds the length of prospective follow-up
c
Time to recurrence was calculated from the time participants fulfilled criteria for recovery until they met full criteria for a new episode.
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